Global stocks have bounced back sharply since the tariff-driven panic in April sent markets to fresh lows, rewarding dip buyers who stepped in and seized the moment.
Now, as the market moves sideways just below all-time highs, those who missed April’s rebound are asking the obvious question: When will the next dip-buying opportunity arise?
But here’s the truth: hoping for another panic isn’t a strategy. A smarter move is to stay ahead by targeting undervalued stocks that the market may have mispriced. Oversold, fundamentally sound companies often hide in plain sight—if you know where to look.
That’s where Investing.com’s proprietary Fair Value tool can prove a game changer.
By applying up to 17 investment-grade fundamental and momentum models, it provides a real-time price calculation for every stock in the market—making it simple and quick to spot market mispricing.
Many investors have already used these signals to uncover hidden gems during market downturns—stocks the market had overlooked, but Fair Value flagged early.
Take Banco Santander (BME:) and Gilead Sciences (NASDAQ:), for example. Both were identified as undervalued by the Fair Value tool and didn’t just hit their projected upside—they exceeded it.
Below is how their stories played out:
1. Banco Santander: Deep Discount Attracts Dip-Buyers, Stock Soars 67%
Systematic valuation frameworks become especially useful when markets misprice fundamentally sound companies. Banco Santander in April 2024 is a good example.
At the time, Santander was trading at just $4.79 per share despite reporting solid financials—$49.65 billion in revenue and earnings per share (EPS) of $0.73. This discrepancy placed the stock well below its estimated intrinsic value.
InvestingPro’s Fair Value model, which draws on up to 17 institutional-grade valuation methods and accounts for factors like market positioning, flagged a potential upside of 35%.
Over the following 11 months, the stock rose steadily to $6.89, surpassing the initial projection with a gain of 49%.
As fundamentals continued to improve—revenue increasing to $52.62 billion and EPS reaching $0.80—Santander extended its rally to $7.95. This marked a total return of 67%, exceeding the original upside estimate by over 30 percentage points.
As the stock appreciated, Fair Value estimates were updated in real time and eventually shifted into overvalued territory. The current model indicates a potential downside of 10.4%, suggesting a reassessment may be warranted.
Source: InvestingPro
This example illustrates how systematic valuation tools can help investors identify pricing inefficiencies—and how ongoing updates to those models can inform decisions as conditions evolve.
2. Gilead Sciences: Strong Follow-Through on Undervalued Signal Delivers 42.83% Surge
Back in November 2023, Gilead Sciences flashed on the Fair Value radar as deeply undervalued, trading 38% below its intrinsic worth.
Investors who acted on that signal were rewarded. By May 28, 2025, the stock had delivered a return of +42.8%, fueled by clinical breakthroughs, bullish analyst sentiment, and a rapidly expanding oncology pipeline.
In November 2023, the market largely overlooked it, but not for long. By May 2025, the stock had rallied +42.8%, driven by major clinical wins and renewed investor interest.
It’s cancer drug Trodelvy, paired with Keytruda, slashed breast cancer progression by 35% in a key trial, prompting calls for it to become the new standard of care.
Meanwhile, excitement built around lenacapavir, Gilead’s long-acting HIV prevention shot, fuelling the bullish case.
Analysts quickly revised their views, with price targets jumping as high as $135 at the beginning of 2024. Strong Q1 earnings and a booming oncology business—now generating over $3B annually—added fuel to the rally.
As the broader biotech sector traded at a steep discount to the , value hunters piled in.
While risks remain, including a looming patent expiration for Biktarvy and muted 2025 revenue growth, Gilead’s performance shows how the Fair Value tool can spotlight opportunity before the crowd catches on.
As of now, the stock remains fairly valued, based on the Fair Value tool’s current assessment.
Bottom Line
The market won’t always hand you the perfect dip. But as the cases of Banco Santander and Gilead Sciences show, you don’t need to wait for chaos to uncover opportunity.
For just under $10 a month, Fair Value gives investors an edge by cutting through the noise and highlighting where mispricings may exist, before the rest of the market catches on.
Instead of chasing the next panic, position yourself to act with confidence, because when the market does misprice an individual stock, you’ll be ready to spot the opportunity.
